CANAKINUMAB VS TRIAMCINOLONE ACETONIDE FOR TREATMENT OF ACUTE FLARES AND PREVENTION OF RECURRENT FLARES IN "DIFFICULT TO TREAT" GOUTY ARTHRITIS

被引：0
|
作者：
Schlesinger, N.
De Meulemeester, M. [1 ]
Shamim, T. [2 ]
Pikhlak, A. [3 ]
Arulmani, U. [4 ]
Richard, D. [4 ]
Murphy, V [4 ]
Sallstig, P. [4 ]
So, A. [5 ]
机构：
[1] UMDNJ, RWJMS, New Brunswick, NJ USA
[2] Heartland Clin Res, Omaha, NE USA
[3] MSUMD, Moscow, Russia
[4] Novartis, Basel, Switzerland
[5] CHU Vaudois, CH-1011 Lausanne, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2010年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S23 / S23
页数：1
相关论文
共 41 条
  • [1] Efficacy of canakinumab (ACZ885) compared to triamcinolone acetonide for treatment of acute flares and prevention of recurrent flares in gouty arthritis patients
    So, A.
    De Meulemeester, M.
    Pikhlak, A.
    Yucel, A. E.
    Arulmani, U.
    Richard, D.
    Murphy, V.
    Sallstig, P.
    Schlesinger, N.
    SWISS MEDICAL WEEKLY, 2010, 140 : 8S - 8S
  • [2] CANAKINUMAB (ACZ885) VS TRIAMCINOLONE ACETONIDE FOR TREATMENT OF ACUTE FLARES AND PREVENTION OF RECURRENT FLARES IN GOUTY ARTHRITIS PATIENTS REFRACTORY TO OR CONTRAINDICATED TO NSAIDS AND/OR COLCHICINE
    So, Alexander
    Meulemeester, Marc D.
    Bodalia, Bhavesh
    Shamim, Talha
    Pikhlak, Andrey
    Yucel, A. Eftal
    Arulmani, Udayasankar
    Richard, Dominik
    Murphy, Valda
    Sallstig, Peter
    Schlesinger, Naomi
    RHEUMATOLOGY, 2010, 49 : I60 - I61
  • [3] Canakinumab for the Treatment of Acute Flares in Difficult-to-Treat Gouty Arthritis Results of a Multicenter, Phase II, Dose-Ranging Study
    So, Alexander
    De Meulemeester, Marc
    Pikhlak, Andrey
    Yucel, A. Eftal
    Richard, Dominik
    Murphy, Valda
    Arulmani, Udayasankar
    Sallstig, Peter
    Schlesinger, Naomi
    ARTHRITIS AND RHEUMATISM, 2010, 62 (10): : 3064 - 3076
  • [4] Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares
    Lyseng-Williamson, Katherine A.
    BIODRUGS, 2013, 27 (04) : 401 - 406
  • [5] Canakinumab: A Guide to Its Use in Acute Gouty Arthritis Flares
    Katherine A. Lyseng-Williamson
    BioDrugs, 2013, 27 : 401 - 406
  • [6] CANAKINUMAB PRE-FILLED SYRINGE VS TRIAMCINOLONE ACETONIDE IN THE TREATMENT OF ACUTE GOUTY ARTHRITIS ATTACKS: RESULTS FROM A POST-HOC ANALYSIS IN DIFFICULT-TO-TREAT PATIENTS
    Sunkureddi, P.
    Toth, E.
    Brown, J.
    Kivitz, A.
    Stancati, A.
    Richard, D.
    Lheritier, K.
    Moericke, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1083 - 1083
  • [7] EFFECT OF CANAKINUMAB VS TRIAMCINOLONE ACETONIDE FOR TREATMENT OF GOUTY ARTHRITIS IN PATIENTS WHO ARE UNABLE TO USE NSAIDS AND COLCHICINE OR WITH SEVERE GOUTY ARTHRITIS
    Schlesinger, N.
    Alten, R.
    Bardin, T.
    Bloch, M.
    Shpilsky, A.
    Krammer, G.
    Kiechle, T.
    So, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 439 - 439
  • [8] Canakinumab (ACZ885) vs colchicine in the prevention of flares in gouty arthritis patients initiating allopurinol therapy
    So, A.
    Lin, H-Y
    De Meulemeester, M.
    Nasonov, E.
    Rovensky, J.
    Mysler, E.
    Arulmani, U.
    Krammer, G.
    Murphy, V.
    Sallstig, P.
    Schlesinger, N.
    SWISS MEDICAL WEEKLY, 2010, 140 : 2S - 2S
  • [9] Comparison of Pain Intensity, Incidence of New Flares, Safety and Tolerability of Canakinumab Vs Triamcinolone Acetonide in Gouty Arthritis Patients with Cardiovascular Diseases or with Cardiovascular Risk Factors.
    Schlesinger, N.
    Brown, J. P.
    Bardin, T.
    Kiechle, T.
    Shpilsky, A.
    Alten, R.
    So, A.
    ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S401 - S401
  • [10] Surrogate markers of comorbidities: Impact of canakinumab versus triamcinolone acetonide in acute gouty arthritis patients
    So, A.
    Schlesinger, N.
    Alten, R.
    Schumacher, H. R.
    Bloch, M.
    Gimona, A.
    Krammer, G.
    Tao, A.
    Stricker, K.
    Bardin, T.
    SWISS MEDICAL WEEKLY, 2011, 141 : S3 - S3
12345